Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study

被引：7
|
作者：
Zhou, Qing
Yang, Nong
Zhao, Jun
Zhao, Mingfang
Yu, Yan
Yuan, Ying
Wang, Huijuan
Li, Xingya
Dong, Xiaorong
Sun, Longhua
Zhang, Tongmei
Huang, Dingzhi
Chu, Qian
Huang, Jingjing
Zhang, Sujie
Huang, Mengna
Shen, Yuping
Wu, Yi-Long
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT030
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Dong, Xiaorong
    Wang, Huijuan
    Yuan, Ying
    Yu, Yan
    Zhang, Meijiang
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
    Yuan, Y.
    Deng, Y.
    Jin, Y.
    Pan, Y.
    Wang, C.
    Wang, Z.
    Zhang, Z.
    Meng, X.
    Hu, Y.
    Zhao, M.
    Wang, H.
    Yang, N.
    Wu, D.
    Dong, X.
    Huang, D.
    Sun, M.
    Liu, L.
    Hua, D.
    Guo, Z.
    Ding, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1512 - S1512
  • [3] Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R-H.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Shen, Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1662
  • [4] Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.
    Yuan, Ying
    Deng, Yanhong
    Jin, Yongdong
    Pan, Yueyin
    Wang, Cunji
    Wang, Zhiwu
    Zhang, Zhiye
    Meng, Xiangjiao
    Hu, Yi
    Zhao, Mingfang
    Wang, Huijuan
    Yang, Nong
    Wu, Dongde
    Dong, Xiaorong
    Huang, Dingzhi
    Sun, Meili
    Liu, Lian
    Hua, Dong
    Guo, Zengqing
    Ding, Ke-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [6] Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results
    Heath, E. I.
    Blumenschein, G. R., Jr.
    Cohen, R. B.
    LoRusso, P. M.
    LoConte, N.
    Kim, S. T.
    Chao, R.
    Wilding, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
    Zhou, Qing
    Meng, Xiangjiao
    Sun, Longhua
    Huang, Dingzhi
    Yang, Nong
    Yu, Yan
    Zhao, Mingfang
    Zhuang, Wu
    Guo, Renhua
    Hu, Yi
    Pan, Yueyin
    Shan, Jinlu
    Sun, Meili
    Yuan, Ying
    Fan, Yun
    Huang, Jianan
    Liu, Lian
    Chu, Qian
    Wang, Xiuwen
    Xu, Chongrui
    Lin, Jiaxin
    Huang, Jingjing
    Huang, Mengna
    Sun, Jiya
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1630 - 1639
  • [8] Docetaxel and ifosfamide in patients with advanced solid tumors: Results of a phase I study
    Pronk, LC
    Schrijvers, D
    Schellens, JHM
    de Bruijn, EA
    Planting, AST
    Locci-Tonelli, D
    Groult, V
    Verweij, J
    van Oosterom, AT
    SEMINARS IN ONCOLOGY, 1998, 25 (01) : 23 - 28
  • [9] Phase I study of camrelizumab in patients with advanced solid tumors
    Yuxiang Ma
    Jiaxin Cao
    Yang Zhang
    Qianwen Liu
    Wenfeng Fang
    Yunpeng Yang
    Yuanyuan Zhao
    Qing Yang
    Hongyun Zhao
    Li Zhang
    Signal Transduction and Targeted Therapy, 8
  • [10] Phase I study of camrelizumab in patients with advanced solid tumors
    Ma, Yuxiang
    Cao, Jiaxin
    Zhang, Yang
    Liu, Qianwen
    Fang, Wenfeng
    Yang, Yunpeng
    Zhao, Yuanyuan
    Yang, Qing
    Zhao, Hongyun
    Zhang, Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
12345